1. Centers for Disease Control and Prevention (CDC). HIV surveillance report, 2017; vol. 29. Table 22a. Persons living with diagnosed HIV infection, by year and selected characteristics, 2012–2016—United States. November 2018. https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-2017-vol-29.pdf. Accessed July 18, 2019.
2. US Census Bureau. Annual estimates of the resident population by single year of age and sex for the United States: April 1, 2010 to July 1, 2018 (NC-EST2018-AGESEX-RES). Released: April 2019. https://www.census.gov/data/datasets/time-series/demo/popest/2010s-national-detail.html. Accessed August 13, 2019.
3. Hall HI, Frazier EL, Rhodes P, et al. Differences in human immunodeficiency virus care and treatment among subpopulations in the United States. JAMA Intern Med. 2013;173(14):1337–44.
4. Scherrer AU, von Wyl V, Yang WL, et al. Emergence of acquired HIV-1 drug resistance almost stopped in Switzerland: A 15-year prospective cohort analysis. Clin Infect Dis. 2016;62(10):1310–7.
5. Hogg RS, Bangsberg DR, Lima VD, et al. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med. 2006;3(9):e356.